Historical amgn News Stories
Amgen Q3 Strength: Upgrades, Dividend Pipeline Now
Amgen (AMGN) saw a string of analyst upgrades and raised price targets after a solid Q3 showing: Repatha and Tezspire posted strong growth, free cash flow jumped to $4.2B, and pipeline assets (bemarituzumab, MARITIDE) advanced. Management confirmed a $2.38 Q4 dividend and will present at Citi on Dec. 3. Insider sales were modestly notable. These concrete developments underpin renewed investor confidence while offering specific near-term catalysts.
Amgen Surge: Repatha Data, Q3 Cash Lift AMGN
Amgen rallied after Repatha's primary‑prevention data and solid Q3 results. Strong sales, rising free cash flow, and a dividend boost support AMGN's DJ30 role, while analysts remain measured on upside.
Amgen Repatha Win Sparks Stock Rally; Q3 Beats Now
Amgen’s Q3 beat-and-raise and landmark VESALIUS‑CV results for Repatha drove a sharp AMGN rally. The clinical win in primary prevention and stronger guidance lifted investor sentiment, prompting technical breakouts and mixed analyst reactions.
Amgen Unveils $600M Research Hub; Stock Dips
Amgen announced a $600 million research and innovation hub in Thousand Oaks this week, prompting a modest near‑term pullback in AMGN shares. The investment signals a long‑term R&D commitment while investors weigh short‑term capital spending and upcoming earnings.